Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.

International Urogynecology Journal and Pelvic Floor Dysfunction
Rebecca G RogersJon D Morrow

Abstract

Improvements in overactive bladder (OAB) symptoms and health-related quality of life (HRQL) were assessed during a 24-week study of tolterodine extended release (TOL ER) in sexually active women with OAB and urgency urinary incontinence (UUI). A 12-week, double-blind, randomized, placebo-controlled trial was followed by a 12-week open-label phase. Sexually active women reported symptoms for >or=3 months. Subjects completed bladder diaries and HRQL measures at baseline and weeks 12 and 24. One hundred sixty-one women received TOL ER for 24 weeks. Women reported significant improvements in all end points at week 12 that were maintained or improved at 24 weeks. At week 24, 70% of subjects reported no UUI episodes. TOL ER resulted in improvements in OAB symptoms and HRQL that were maintained or greater with 6 months of use. Long-term compliance with OAB pharmacotherapy may be important for optimal treatment outcomes.

References

Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Mar 15, 2001·Urology·P Van KerrebroeckUNKNOWN Tolterodine Study Group
Mar 23, 2001·American Journal of Obstetrics and Gynecology·R G RogersC Qualls
Jan 25, 2002·International Urogynecology Journal and Pelvic Floor Dysfunction·G R RogersC Qualls
Sep 11, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·K CoyneP Abrams
Jun 18, 2003·World Journal of Urology·W F StewartA J Wein
May 1, 2004·American Journal of Obstetrics and Gynecology·Kaven Baessler, Stuart L Stanton
Sep 20, 2005·Journal of Sex & Marital Therapy·Tara SymondsFrances Quirk
Nov 1, 2006·American Journal of Obstetrics and Gynecology·Rebecca G RogersMatthew Barber
May 15, 2007·The Journal of Sexual Medicine·Karin S CoyneRebecca Rogers
Jul 12, 2008·BJU International·Ramandeep K BasraCon Kelleher
Aug 8, 2008·International Urogynecology Journal and Pelvic Floor Dysfunction·Rebecca RogersTamara Bavendam
Jan 1, 2006·Neurourology and Urodynamics·Paul AbramsPeter Sand

❮ Previous
Next ❯

Citations

May 30, 2013·Current Urology Reports·Jaclyn ChenAlan Shindel
Oct 17, 2012·International Journal of Clinical Practice·S JohnstonS Bukofzer
Aug 1, 2015·Archives of Gynecology and Obstetrics·Swati Jha
Apr 16, 2011·The Journal of Sexual Medicine·Karin S CoyneSteven A Kaplan
Jan 12, 2013·International Journal of Clinical Practice·C TannenbaumL Cardozo
Aug 14, 2012·BJU International·Silvia ProiettiProkar Dasgupta
Apr 27, 2017·Neurourology and Urodynamics·Angie RantellLinda Cardozo
Mar 17, 2016·Investigative and Clinical Urology·Tae Heon Kim, Kyu-Sung Lee
May 17, 2011·Female Pelvic Medicine & Reconstructive Surgery·Victoria L HandaHolly E Richter
Sep 14, 2015·Women's Midlife Health·Christine M ChuUduak U Andy
Aug 12, 2009·Expert Opinion on Pharmacotherapy·Doreen E Chung, Alexis E Te

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.